Tenofovir is one of the first-line drugs for antiviral therapy in patients with chronic hepatitis B. In 2008, the US Food and Drug Administration approved Tenofovir for CHB treatment. In 2014, Tenofovir was approved by the China Food and Drug Administration for antiviral treatment of CHB patients.
Tenofovir is tenofovir disoproxil fumarate, which is rapidly hydrolyzed to tenofovir after oral administration and is phosphorylated into the active product tenofovir diphosphate in the cells, and deoxygenated with 5'-triphosphate. The glycosidic acid competes for incorporation into the viral DNA strand, which inhibits viral replication due to its lack of 3'-OH, which leads to inhibition of DNA strand elongation. Tenofovir medications are generally not affected by regular diets.
Recommended dose for adults and children aged 12 years and older (35 kg or more): 300 mg (one tablet) each time, once daily, orally, on an empty stomach or with food.